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Abstract
Blocking the function of the myelin protein Nogo-A or its signaling pathway is a promisingmethod to overcome an
important neurite growth inhibitory factor of the adult central nervous system (CNS), and to enhance axonal
regeneration and plasticity after brain or spinal cord injuries. Several studies have shown increased axonal regen-
eration and enhanced compensatory sprouting, along with substantially improved functional recovery after treat-
ment with anti-Nogo-A antibodies, Nogo-receptor antagonists, or inhibition of the downstream mediator RhoA/
ROCK in adult rodents. Proof-of-concept studies in spinal cord-injured macaque monkeys with anti-Nogo-A anti-
bodies have replicated these findings; recently, clinical trials in spinal cord-injured patients have begun. However,
the optimal time window for successful Nogo-A function blocking treatments has not yet been determined. We
studied the effect of acute as well as 1- or 2-weeks delayed intrathecal anti-Nogo-A antibody infusions on the
regeneration of corticospinal tract (CST) axons and the recovery of motor function after large but anatomically
incomplete thoracic spinal cord injuries in adult rats. We found that lesioned CST fibers regenerated over several
millimeters after acute or 1-week-delayed treatments, but not when the antibody treatment was startedwith a delay
of 2 weeks. Swimming and narrow beam crossing recoveredwell in rats treated acutely or with a 1-week delaywith
anti-Nogo-A antibodies, but not in the 2-week-delayed group. These results show that the time frame for treatment
of spinal cord lesions with anti-Nogo-A antibodies is restricted to less than 2 weeks in adult rodents.
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Introduction
The failure of neurons to regenerate after axotomy inthe central nervous system (CNS) is amajor reason for the
lack of substantial functional recovery after large brain or
spinal cord lesions in adult mammals. Several factors con-
tribute to this failure: Some CNS neurons are intrinsically
reluctant to grow and to sufficiently upregulate regeneration-
associated proteins following an injury (Plunet et al., 2002).
The formation of growth-inhibiting scar tissue at the site of
CNS injury, and the presence of myelin-associated growth
inhibitors block the regeneration of injured axonal projections.
Enzymes that degrade scar-associated chondroitin sulfate
proteoglycans (CSPGs) injected into the injured tissue led to
enhanced fiber growth around injury sites (Yiu andHe, 2006).
The blockage of the myelin-associated protein Nogo-A, a key
growth-inhibiting molecule in the oligodendrocyte cell
membrane of adult higher vertebrates, by acute intrathecal
infusion of neutralizing monoclonal antibodies or by peptides
or fusion proteins blocking Nogo-A or its receptor NgR after
spinal cord lesions led to enhanced sprouting and regenera-
tion of injured axons, accompanied by an improved func-
tional recovery in adult rodents and macaque monkeys
(Freund et al., 2006; Gonzenbach and Schwab, 2008; Liebscher
et al., 2005; Schwab, 2004). Nogo-knockout lines produced
conflicting results and remain a subject of ongoing studies.
While Nogo-A (Simonen et al., 2003) and Nogo-A and -B
(Cafferty and Strittmatter, 2006; Cafferty et al., 2007,2010; Kim
et al., 2003) knockout lines showed an increased or partially
increased regenerative and plastic phenotype in some labs, no
effects were seen inNogo-knockout lines generated in another
laboratory (Lee et al., 2009; Zheng et al., 2003). Triple knock-
outs for Nogo, MAG, and OMgp showed major regrowth
(Cafferty et al., 2010), or only enhanced compensatory axon
sprouting (or intraspinal plasticity), but no long-distance re-
generation (Lee et al., 2010). These mixed results could be
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explained by compensatory upregulation of other Nogo splice
variants (Simonen et al., 2003), as well as other repulsive
molecules (Montani and Schwab, unpublished observations),
produced by the different genetic backgrounds of the mouse
lines used by the different groups (Dimou et al., 2006), and by
the different lesion paradigms used (Cafferty and Strittmatter,
2006). Constitutive, lifelong genetic knockouts are known to
often produce milder (or even no) phenotypes due to com-
pensatory mechanisms that are less likely to occur after acute
application of function-blocking drugs, antibodies, peptides,
or fusion proteins (for a discussion of this issue, see Schwab,
2010 and Tuszynski, 2010).
As axons of axotomized upper motoneurons progressively
retract from the lesion site (Pallini et al., 1988; Seif et al., 2007)
and often atrophy (Wannier et al., 2005), they may become less
responsive to anti-Nogo-A treatmentwith increasing time after
injury. In addition, scar formation and accumulation of CSPGs
at the injury site may further impede successful regeneration
(Busch and Silver, 2007), which could further reduce the effi-
cacy of neurite growth-enhancing treatments. Yet for use in
human patients, determining the time frame for clinically
successful interventions is pivotal, as victims of spinal cord
injury (SCI) can usually not be treated immediately after injury.
Previous animal studies indicate that injured neurons may in-
deed retain the ability to regenerate for weeks or months after
injury, if they are stimulated by adequate interventions (Houle,
1991; Kwon et al., 2002; Ye and Houle, 1997; Ylera et al., 2009).
One-week-delayed treatment with the Nogo receptor antago-
nist NEP1-40 led to increased axonal regeneration and im-
proved locomotor function recovery that was comparable to
acute treatment (Li and Strittmatter, 2003). However, the op-
timal time window for treatment with Nogo-A-neutralizing
agents is currently unknown.
We report that in adult rats the window of opportunity for
treatment with anti-Nogo-A antibodies is clearly limited after
spinal cord lesion, and that delaying the application pro-
gressively reduces its effect on the functional recovery and the
regeneration of corticospinal tract (CST) fibers.
Methods
Animals and animal care
All procedures described herein were approved by the
Veterinary Office of the Canton of Zu¨rich, Switzerland. Adult
female Lewis rats (180–200 g, aged 8–10 weeks) were kept in
groups of 4–5 animals in standard cages on a 12-h light/dark
cycle with access to water and food ad libitum.
Experimental design
A total of 63 rats divided into six groups were treated in-
trathecally for 2 weeks with anti-Nogo-A or control anti-
bodies, starting immediately or with a delay of 1 or 2 weeks
after an incomplete thoracic (T8) SCI.
The animals were handled and trained on the narrow beam
and the swim test for 3 weeks prior to surgery. Preoperatively,
a third of the rats were randomly assigned to the immediate
treatment groups. The rats that received the treatment starting
1 or 2weeks after spinal cord lesionwere randomly assigned to
the treatment groups in pairs according to their motor function
deficits 6 days after injury (with the assigning investigators
blinded to the treatment group). The narrow beam perfor-
mance was the principal measure used to randomize animals
in pairs (i.e., animalswith equal or similar scoreswere assigned
to either the IgG- or the anti-Nogo-A-treated groups). As dif-
ferent behavioral scores do not necessarily correlate, the read-
outs from the Basso-Beattie-Bresnahan (BBB) subscore and
swim testwere also used in cases forwhich several animals had
similar scores. This randomized assignment allowed the com-
parison of treatment groups with equal motor function deficits
at the start of antibody application.All ratswere number coded
and kept in randomly mixed groups. All experimenters were
blinded to the treatment throughout the experiment. The ex-
perimental design is shown in Figure 1A.
Antibodies, antibody administration, and CSF
antibody concentration
Mouse monoclonal antibody 11C7 directed against amino
acids 623–640 of the rat Nogo-A sequence (Oertle et al., 2003),
and control monoclonal IgG antibodies directed against the
plant protein wheat auxin were infused at a concentration of
3mg/mL. The anti-Nogo-A antibody 11C7 is monospecific
for Nogo-A on Western blots, and does not cross-react with
other Nogo splice variants (Dodd et al., 2005). The function-
blocking capacity of this anti-Nogo-A antibody is due to steric
blockage of the interaction of Nogo-A with its receptor, and
the downregulation of Nogo-A from the cell surface by in-
ternalization of the Nogo-A/antibody complex (Liebscher
et al., 2005; Weinmann et al., 2006).
A total of 6mg of antibody dissolved in 2mL PBS was
continuously delivered over 2weeks into the intrathecal space
using subcutaneously implanted osmoticmini-pumps (5lL/h,
ALZET 2ML2; DURECT Corp., Cupertino, CA) connected
to a subdurally-implanted catheter as previously described
(Liebscher et al., 2005).
CSF samples in the 1-week-delay groups were collected by
puncturing the cisterna magna immediately after pump re-
moval. The CSF antibody concentration was determined with
sandwich enzyme-linked immunosorbent assay.
Spinal cord lesion surgery
All surgical procedures were performed under anesthesia
using Hypnorm (120 lL/200 g body weight; Janssen Phar-
maceutica, Beerse, Belgium) and Dormicum (0.75mg per
200 g body weight; Roche Pharmaceuticals, Basel, Switzer-
land). T-shaped lesions of the thoracic (T8) spinal cord that
transected the dorsal, dorsolateral, and ventromedial parts of
the spinal cord were performed on 8- to 10-week-old rats es-
sentially as described previously (Liebscher et al., 2005), but
with more extensive lesioning of the lateral funiculi. This le-
sion paradigmwas chosen because it completely interrupts all
parts of the CST, including the ventral fibers. This lesion
paradigm produced well-defined, moderate functional defi-
cits with good recovery of motor and bladder function, thus
keeping animal suffering to a minimum. Postoperatively, the
bladder was manually expressed for 2 weeks. Antibiotics
(Baytril, 5mg/kg; Bayer AG, Leverkusen, Germany) were
given subcutaneously for 7 days to prevent bladder infection.
Exclusion criteria for behavioral assessment
The locomotor impairments varied substantially between
rats, in spite of standardized surgical procedures. All animals
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had complete lesions of the dorsal, dorsolateral, and ventral
funiculus containing the CST. To compare animals with
similar functional deficits, rats with a performance of >9 on
the narrow beam test 6 days after experimental SCI were ex-
cluded post hoc (n= 13). In addition, 2 rats with recurrent
bladder infections were excluded as well. The exclusions were
done prior to statistical analysis on the number-coded rats.
Assessment of locomotor function recovery
Locomotor function was scored directly (narrow beam test
and BBB), or videotaped and analyzed with a computer (swim
test). The number of animals was as follows: acute anti-Nogo-
A: n= 9, acute IgG control: n= 7, 1-week-delayed anti-Nogo-A:
n= 7, 1-week-delayed IgG control: n= 9, 2-weeks-delayed anti-
Nogo-A: n= 9, 2-weeks-delayed IgG control: n= 7.
Swim test. Intact rats use their hindlimbs and the tail for
swimming, while their forelimbs are held immobile under the
chin. Due to their buoyancy, rats are able to swim even after a
severe SCI. The basic swimming pattern with alternating
hindlimb strokes is usually not affected except for short pe-
riods during which the rats swim in a ventroflexed position
FIG. 1. Study design, lesion size, antibody tissue penetration, and cerebrospinal fluid (CSF) antibody concentrations. (A)
Scheme summarizing the different treatment groups and the sequence of experimental steps. After a large, incomplete spinal
cord injury at T8, adult rats were treated acutely or with a delay of 1 or 2 weeks with either a monoclonal antibody against
Nogo-A or with a control antibody. Locomotion was assessed with different behavioral tests over a time period of 10 weeks
after injury. Ten weeks after injury, the corticospinal tract (CST) was anterogradely traced to assess the regeneration of lesioned
axons. (B) Scheme of the T-shaped spinal cord lesion at T8. This lesion (grey) interrupts the major CST in the dorsal funiculus, as
well as the minor projections in the dorsolateral and ventral funiculus (red). The lateral and ventral funiculi are partially spared
and act as bridges for regenerating axons. Examples of reconstructed lesions are shown in Figure 5. (C) Lesion extent in the six
experimental groups. (D) Mean antibody concentration (lg/mL) in the CSF collected from the cisterna magna after 14 days of
intrathecal infusion, started 1 week after spinal cord injury. (E) Antibody tissue penetration into brain and thoracic spinal cord
of injured rats after 14 days of continuous infusion started 2 weeks after injury. The anti-Nogo-A antibodies penetrated well into
the central nervous system (CNS) tissue, and were retained at high and intermediate levels in the spinal cord and brain
parenchyma, respectively. Control antibody levels were low in the spinal cord, and almost undetectable in the brain, suggesting
that they were washed out quickly, as they did not bind to the CNS tissue. Bars indicate mean– standard error of the mean.
Antibody density in E is color coded: red indicates high antibody (ab) density, and dark blue indicates low antibody density.
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with often coupled hindlimb strokes (Gonzenbach et al.,
2010). This allows scoring the deviation from normal hin-
dlimb usage and assessment of its recovery over time as de-
scribed by Liebscher and associates (Liebscher et al., 2005).
The rats were videotaped while swimming in an acrylic glass
basin (150 · 40· 13 cm, water temperature 28–30C). Swim-
ming velocity was calculated by measuring the time required
for swimming a distance of 60 cm.Hindlimb usagewas scored
as described by Liebscher and colleagues (Liebscher et al.,
2005): 4=normal hindlimb usage; 3=hindlimb strokes devi-
ate laterally but the hindlimbs are underneath the body;
2 =hind paws are lateral to the body and the distance between
the hindlimbs is increased; 1= large distance between the
hindlimbs (i.e., the hind paws and legs are entirely lateral to
the body).
Narrow beam test. To assess deficits in balance and fine
motor control, the rats had to cross an elevated tapered beam
(1.4m long) labeled with 24 equally spaced segments, from
the wide (6 cm) to the narrow (1.5 cm) end. Intact rats have no
difficulties crossing the beam in its entire length, whereas
spinal-cord-lesioned rats step down onto a ledge fixed un-
derneath as the beam gets narrower, depending on their
functional deficits. They were scored (0–24) according to the
segment where they first stepped down. The average of 10
runs is reported.
BBB and BBB subscore. The hindlimb locomotor re-
covery was assessed with the BBB open field locomotor scale
(Basso et al., 1995) by two blinded observers before and 1, 5,
and 10 weeks after injury. The rats were individually placed in
an open field for 4min and joint movements, stepping capa-
bility, toe clearance, coordination, trunk stability, and tail usage
were scored. In addition, we determined the BBB subscore,
which reflects toe clearance, hindlimb rotation, and tail usage,
regardless of coordination (Basso, 2004). The average score of
the right and left hindlimbs is reported for each animal.
Anterograde corticospinal tract tracing
Ten weeks after SCI, the corticospinal tract was ante-
rogradely traced as previously described (Liebscher et al.,
2005). Briefly, a total volume of 2.0 lL of 10% BDA (MW
10000; Molecular Probes, Eugene, OR) dissolved in 0.01M
PBS was injected at four sites of the hindlimb area of the
sensorimotor cortex using a Hamilton syringe. Care was ta-
ken not to inject BDA into the lateral ventricles to avoid ar-
tefactual labeling of neurons via the CSF (Steward et al., 2007).
Three weeks later, the rats were deeply anesthetized with
pentobarbital and perfused with heparinized Ringer’s solu-
tion, followed by 4% paraformaldehyde. The spinal cords
were dissected and processed as previously described (Lieb-
scher et al., 2005). Sagittal sections were cut at 50lm on a
cryostat, and further processed by the avidin-biotinmethod to
reveal BDA-labeled fibers using the semi-free-floating tech-
nique (Herzog and Brosamle, 1997).
Quantification of corticospinal tract regeneration
The number of BDA-labeled CST axons was counted at
0.5mm, 2mm, and 5mm caudal to the lesion site on complete
series of 50-lm-thick sagittal sections at 400 · magnification
for each spinal cord. If axons were arborized, each segment
was counted separately. A segment was defined as a contin-
uous BDA-positive fiber that is not interrupted by branches.
The vast majority of traced fibers were thin and followed an
irregular course. Rarely, a small number of spared CST fibers
were found in the ventral funiculus. They were clearly iden-
tified by their typical straight and regular trajectory and were
not counted.
To correct for inter-individual tracing variability, the total
number of BDA-labeled axonswas quantified on two adjacent
50-lm cross-sections in the upper thoracic spinal cord several
segments rostral to the injury site using a 63· objective. The
number of CST fibers counted caudal to the injury was then
divided by the number of BDA-labeled fibers above the lesion
to calculate the fraction of regenerated fibers. This calculated
fraction of regenerated fibers was reported as a percentage of
regenerated fibers.
The animal numbers were as follows: acute anti-Nogo-A:
n = 8, acute IgG control: n= 6, 1-week-delayed anti-Nogo-A:
n = 7, 1-week-delayed IgG control: n= 6, 2-weeks-delayed
anti-Nogo-A: n = 11, 2-weeks-delayed IgG control: n = 6.
Camera lucida reconstructions
The labeled corticospinal axons of three adjacent para-
sagittal spinal cord sections were projected onto a single plane
and plotted together with the contour of the lesion and the
spinal cord surface using a camera lucida tubus attached to
the microscope.
Immunohistochemistry
To determine the upregulation of the scar-associated pro-
teoglycan CS-56, rats were euthanized at 3, 7, and 14 days
after SCI as described above. For each time point, two rats
were used. The tissue was fixed and processed as described
above, and cut at 50lm in the sagittal plane. Free-floating
sections were incubated with the primary monoclonal mouse
IgMCS-56 (1:50; Sigma-Aldrich, St. Louis, MO), followed by a
biotin-coupled donkey anti-mouse secondary antibody (1:200;
Jackson ImmuoResearch, West Grove, PA). The biotin-coupled
secondary antibody was detected using Cy3-conjugated strep-
tavidin (1:300; Jackson ImmuoResearch).
To determine the tissue penetration of the intrathecally-
infused antibodies, six rats treated with a delay of 2 weeks
were euthanized 1 h after pump removal. Three animals were
used for each treatment group. The tissue was handled as
described above and cut at 50lm on a cryostat. Free-floating
sections were incubated with a rat-adsorbed anti-mouse an-
tibody coupled to biotin (1:300; Jackson ImmunoResearch).
The biotin-coupled secondary antibody was detected using
the ABC-DAB system (Vector Laboratories, Burlingame, CA).
The immunohistochemical staining procedure was done in
the same batch for anti-Nogo-A- and control antibody-treated
animals. The density of antibody staining was quantified and
color-coded with red indicating high antibody density, and
dark blue indicating low antibody density.
Assessment of lesion completeness
All spinal cord lesions were reconstructed in the coronal
plane to control for appropriate lesion size and shape. The
lesions were reconstructed from the complete section series
used for CST reconstruction at the site of the largest lesion
4 GONZENBACH ET AL.
extent and projected into a single coronal plane. The extent of
the lesion was determined as a percentage of the spinal cord
cross-section using ImageJ software.
Statistical analysis
All statistical tests were carried out with SPSS 14.0. The
locomotor tests were evaluated with a two-way repeated-
measures analysis of variance (ANOVA). The numbers
of regenerated CST fibers was evaluated with the Mann-
Whitney U test.
Results
Lesion size and antibody distribution
All the groups had similar lesion sizes, ranging between
40% and 65% injured tissue (Fig. 1B and C). In spite of stan-
dardized surgeries, the lesion size varied between individ-
ual animals due to secondary effects like ischemic necrosis
and bleeding. However, control antibody- and anti-Nogo-A-
antibody treated groups were not different in their lesion si-
zes. The 2-weeks-delayed groups, both anti-Nogo-A- and
control antibody-treated, had slightly smaller lesions ( p < 0.05
by two-tailed t-test for independent samples) than the acute
and 1-week-delayed groups, which might account for the
slightly better performance on the narrow beam and the BBB
score in the first weeks after injury.
Antibody concentrations in the CSF after 2 weeks of infu-
sion in the 1-week-delayed groups ranged between 3 and
40 lg/mL, and were similar in the anti-Nogo-A- and the
control antibody-treated groups (two-tailed t-test, anti-Nogo-
A antibody 11c7: n = 11, control IgG: n = 12; Fig. 1D).
To rule out the possibility that scar tissue blocks the free
distribution of antibodies within the CSF and the penetration
of antibodies into the tissue 2 weeks after SCI, we did im-
munohistochemical stainings of spinal cord and brain cross-
sections for mouse IgG in the 2-week-delayed group. The
immunohistochemical staining yielded dense signals in the
spinal cord of anti-Nogo-A antibody-treated animals, and
weak signals in control antibody-treated animals, indicating
that anti-Nogo-A antibodies, which bind to cell surface Nogo-
A, are retained more efficiently in the tissue than the control
antibody against wheat auxin (Fig. 1E). Moderate signals
were also detected in the brains of anti-Nogo-A-, but not of
control antibody-treated rats. The strongest immunoreactiv-
ity was observed at the spinal cord and brain surface (Fig. 1E).
The lower antibody staining in the CNS parenchyma com-
pared to the pial surface occurs because the intrathecally-
applied antibodies have to diffuse from the CSF into the
parenchyma. These results are very similar to the ones
obtained earlier (Weinmann et al., 2006).
Locomotor recovery
The swim test showing the use and position of the hin-
dlimbs, the relatively difficult narrow beam test showing
balance and precision of foot placement, and the BBB score for
open field locomotion were used to assess the effects of anti-
Nogo-A antibody administration at 0-, 1-, and 2-week delays
after SCI.
Narrow beam. The narrow beam paradigm (Fig. 2, top
row) assesses different aspects of locomotor function. Besides
basic stepping function, successful crossing of the narrow
FIG. 2. Locomotor performance on the swim test and the narrow beam test before (baseline) and after injury. Upper row:
Narrow beam test. The rats crossed a tapered narrow beam from the broad to the narrow end. Antibody treatment time is
indicated by black horizontal bars. Middle row: Swim velocity in m/sec. Three runs over 60 cm were averaged. Bottom row:
Score for hindlimb function during swimming. Intact rats swimwith their hindlimbs underneath the body. After the incomplete
thoracic spinal cord injury the distance between the hindlimbs was large and the animals used their forelimbs to compensate for
the weak or failing hindlimbs. Means– standard error of the mean are shown; black dots and crosses represent single animal
values of anti-Nogo-A antibody- and control IgG-treated groups, respectively. Significance levels of the treatment effect (anti-
Nogo-A antibody versus control IgG) as determined by repeated-measures analysis of variance are indicated with large stars
above the bar graphs. Treatment effects at single time points are indicated with small crosses (*p£ 0.05, **p£ 0.01).
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beam requires the capability to maintain balance. Six days
after injury, the narrow beam scores were very low in all
groups. Rats acutely-treated with anti-Nogo-A antibody
scored significantly higher than the control antibody group on
the narrowbeam test from 2weeks on. The delayed treatment,
however, did not improve performance on the narrow beam;
the slight recovery observed in the groups with delayed an-
tibody application was equal for the anti-Nogo-A and the
control groups. The lower score in the first week after injury in
the acutely-treated rats compared to the groups with delayed
treatment is most probably due to the subcutaneously im-
planted mini-pump in combination with the recent SCI. Early
after injury, when balance and finemotor control have not yet
recovered, the pump represents an irritation for the rats and
reduces their ability to cross the beam.
Swim test. The groups with anti-Nogo-A antibody given
acutely or with a 1-week delay progressively improved their
swimming velocity and their hindlimb use over 3–4 weeks
(Fig. 2, lower rows). In contrast, the animals with 2-weeks-
delayed anti-Nogo-A treatment, as well as the control IgG
animals of all the groups, did not improve swimming velocity
and hindlimb function. After injury, the swimming velocity
was about 50% of normal. It recovered to 61–66% in the acute
and 1-week-delayed anti-Nogo-A antibody-treated groups.
The hindlimb score dropped to a very low level in all groups
at 6 days after injury. The recovery of hindlimb function was
significantly better in the acute and 1-week-delayed anti-
Nogo-A antibody-treated groups compared to their respec-
tive control groups. In contrast, the 2-weeks-delayed anti-
Nogo-A antibody-treated group was no different from its
IgG-control group.
Open field locomotion. The BBB score dropped from 21 to
7–10, and the BBB subscore from 12 to 0, at 1 week after injury
in all groups. Tenweeks after spinal cord lesion, most rats had
consistently recovered stepping function, regardless of treat-
ment or treatment onset; most ranked between 11 and 13 in
the BBB score (Fig. 3, lower row), corresponding to no (11),
occasional (12), or frequent (13) hindlimb–forelimb coordi-
nation, respectively. No significant difference with regard to
forelimb–hindlimb coordination, which depends largely on
propriospinal connections running in the spared ventrolateral
tracts ( Juvin et al., 2005), was found between the treatment
groups. As the BBB is not sensitive enough to detect relevant
differences in the functionally important range between 10–14
points, we determined the BBB subscore. In the BBB subscore,
which reflects toe clearance, hindlimb rotation, and tail usage
(important for trunk stability and balance), the acutely and the
1-week-delayed anti-Nogo-A antibody-treated groups both
reached significantly higher scores than the control antibody
groups (Fig. 3, upper row). In contrast, in the 2-week-delayed
anti-Nogo-A antibody treatment group, the BBB subscorewas
comparable to that of the control antibody group.
Corticospinal tract regeneration
The regeneration of the cut CST fibers under different
treatment conditions was investigated 10 weeks after spinal
cord lesion. Only animals showing a complete interruption of
the dorsal, the dorsolateral, and the ventral CST tracts were
included in the analysis. A few animals were lost due to death
during tracing surgery or due to tracing failure. In all ana-
lyzed spinal cords, the transected CST was slightly retracted
from the lesion site and formed numerous retraction bulbs.
Regenerating CST fibers grew in bridges of spared tissue
FIG. 3. Open field locomotion. Upper row: Basso-Beattie-Bresnahan (BBB) subscore measuring toe clearance, hindlimb
rotation, and tail usage, independent of coordination. Lower row: BBB score. Bars indicate means – standard error of the
mean; black dots and crosses represent the single animal values of anti-Nogo-A antibody- and control antibody-treated
animals, respectively. Significance levels of the treatment effect (anti-Nogo-A antibody versus control) are indicated with
stars above the bar graphs and were calculated with repeated-measures analysis of variance (*p £ 0.05; ab = antibody).
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around the lesion site and did not enter the lesion site, as
described previously (Liebscher et al., 2005). Labeled CST fi-
bers observed below the lesion site were consistently of thin
caliber and followed a tortuous course, mostly within the grey
matter (Figs. 4A and 5). Most fibers arborized extensively
within the grey matter forming numerous collaterals. In
control antibody-treated rats, regardless of the antibody in-
fusion onset, very low numbers of labeled CST fibers were
observed below the injury site, as indicated by a low per-
centage of 0.2–1% regenerating fibers (Fig. 4A, bottom row;
Fig. 4B; Fig. 5, top row). In contrast, anti-Nogo-A antibody-
treated rats showed significantly higher numbers of labeled
CST fibers at all analyzed levels below the injury site, if the
treatment was started acutely or with a delay of 1 week after
injury (Figs. 4 and 5). The percentage of regenerated fibers
was highest after acute treatment, reaching means of 7.2–
10.9% ( p < 0.01 at 0.5mm and 2mm, p< 0.05 at 5mm). In the 1-
week-delayed treatment group the regeneration was still
significantly improved in the anti-Nogo-A compared to the
control antibody group, reaching 3.9–5.0% ( p< 0.05 at 0.5mm,
and p < 0.01 at 2mm and 5mm). After 2-weeks-delayed
treatment, the percentage of regenerated fibers was signifi-
cantly higher in the anti-Nogo-A than in the control antibody
group 0.5mm caudal to the injury ( p< 0.05), but not 2 and
5mm caudal to the injury (Fig. 4B).
Chondroitin sulfate proteoglycan immunoreactivity
at the lesion site
To look for molecular mechanisms behind the decreased
anti-Nogo-A response at 2 weeks after injury we stained for
the scar associated proteoglycan CS-56, which is known to be
upregulated after CNS injury. Staining with the CS-56 anti-
body, which recognizes chondroitin-4- and chondroitin-6-
sulfate proteoglycans (Avnur andGeiger, 1984), revealed very
low levels of CSPG in the intact spinal cord (Fig. 6A). Slightly
increased levels of CS-56 immunoreactivity were seen 3 days
after injury; it was restricted to the lesion site and did not
include neighboring spared tissue (Fig. 6B). In contrast, at 1
and 2weeks after injury, the immunohistochemical signals for
CS-56 had augmented substantially and had spread to the
neighboring spared tissue (Fig. 6C and D). This time course of
CSPS expression is in agreement with earlier observations
(Camand et al., 2004).
Discussion
The results obtained with acute intrathecal anti-Nogo-A
antibody infusion after spinal cord injury in adult rats con-
firmed earlier findings: regeneration of injured descending
tract fibers (e.g., of the CST), and enhanced recovery of loco-
motor function. Delaying the start of intrathecal anti-Nogo-A
antibody infusion after the lesion, however, led to a pro-
gressive loss of responsiveness to the treatment both on the
cellular and the functional level. While regeneration and
functional recovery were still strongly increased after 1-week-
delayed anti-Nogo-A antibody treatment, 2-weeks-delayed
treatment led to a minimal increase in fiber regeneration and
no observably improved functional recovery compared to the
control antibody infusion.
On the functional level, intrathecal anti-Nogo-A antibody
administration started immediately after injury substantially
improved several parameters of open-field locomotion, in
particular improved foot placement as assessed by the BBB
subscore, and increased ability to cross the narrow beam.
Restoration of hindlimb motor control was also reflected in
the higher swimming velocity and improved hindlimb usage
during swimming.
FIG. 4. Corticospinal tract (CST) axons caudal to the lesion after acute and 1- or 2-weeks-delayed anti-Nogo-A or control
antibody treatment. (A) Photographs of BDA-traced CST fibers in the lower thoracic spinal cord taken at increasing distances
caudal to the lesion site. Regenerating fibers are typically fine, follow an irregular course, and often arborize extensively in the
grey matter. (B) Quantification of CST axons 0.5mm, 2.0mm, and 5.0mm caudal to the lesion site. The average numbers of
BDA-labeled axons caudal to the lesion site were divided by the total number of labeled CST fibers for each animal in the
dorsal CST and reported as percentage of regenerating fibers. Black dots and crosses represent the single animal values of
anti-Nogo-A antibody- and control antibody-treated animals, respectively. Bars indicate means – standard error of the mean
(*p < 0.05, **p < 0.01 by Mann-Whitney U tests).
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FIG. 5. Camera lucida reconstructions of paramedian sagittal sections through the spinal cord lesion site of rats that
received acute or 1- or 2-weeks-delayed anti-Nogo-A antibody treatment, or acute control IgG treatment. Three adjacent
sections were superimposed. Left: Reconstructed coronal spinal cord sections showing the lesion extent (grey) of the re-
spective animal groups. Substantial numbers of BDA-labeled corticospinal tract fibers are found caudal to the injury site after
acute and 1-week-delayed anti-Nogo-A infusion. After 2-weeks-delayed infusion, some fibers were seen close to the injury
site, but not at more caudal levels.
FIG. 6. Photomicrographs of CS-56 immunoreactivity of paramedian sagittal spinal cord sections at different time points
after injury. (A) In intact animals the chondroitin sulfate proteoglycan (CSPG) levels were low. (B) At 3 days after injury the
CSPG levels were slightly increased at the lesion site. Bridges of intact tissue with low levels of CS-56 are indicated by black
arrows. (C and D) At 1 and 2 weeks after injury, CS-56 levels were substantially increased and had spread from the lesion
edge into the surrounding tissue including the ventral tissue bridges. Inset in B: the dotted line on the coronal spinal cord
section shows the position of the paramedian sagittal sections in B–D (SCI, spinal cord injury).
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In contrast to the findings of Liebscher and associates we
did not observe consistent forelimb/hindlimb coordination in
the acutely treated anti-Nogo-A-treated animals, resulting in
similar overall BBB scores for both treatment groups. Fore-
limb/hindlimb coordination relies mainly on intact pro-
piospinal connections that run in the lateral tracts. Our lesions
were larger, (i.e., 40–65% in the acute treatment groups,
compared to the 40–50% used by Liebscher and colleagues
[2005]), and destroyed the lateral tracts more substantially.
This might explain why none of our animals recovered con-
sistent forelimb/hindlimb coordination.
When the start of the antibody application was delayed by
1 week after injury, an improved functional recovery was
still observed in the swim test and the BBB subscore, for
which the extent of recovery was comparable to that ob-
tained with acute treatment. In contrast, however, the per-
formance on the narrow beam did not improve in the 1-
week-delayed treatment group. Balancing on and crossing
the narrow beam likely requires substantial supraspinal
control such as tactile input from the whiskers, visual in-
formation, vestibular and cerebellar input for balance, and
correct foot placement and grip control. In contrast, the
control of swimming may require fewer supraspinal com-
mands, and depends to a larger extent on the spinal central
pattern generator. The lower percentage of regenerating CST
fibers in the 1-week-delayed compared to the acute treat-
ment with anti-Nogo-A antibodies (5% versus 10%) may
explain the lack of improved recovery of narrow beam
crossing in the 1-week-delayed anti-Nogo-A antibody-
treated animals. This lower, but in comparison to control
animals increased, number of regenerated CST fibers may
still be sufficient to control swimming, but is not adequate
for the more demanding beam crossing task.
In the 2-weeks-delayed groups the lesion size tended to be
slightly smaller than in the other groups, which explains the
slightly better motor performance of these groups. One could
argue that this slightly smaller lesion size in the 2-weeks-
delayed groups might have led to sufficient spontaneous
motor function recovery, and thereby disguised the treatment
effect of anti-Nogo-A antibody treatment. Data from Lieb-
scher and colleagues (Liebscher et al., 2005) suggest that this is
not the case; rats with the same lesion paradigm but smaller
lesion size (40–50% in Liebscher compared to 40–60% in the
2-weeks-delayed group in our study) showed a clear response
to acute anti-Nogo-A antibody treatment. Therefore the lack
of functional recovery is most likely due to the 2-weeks-
delayed treatment.
In parallel with the functional readouts, a progressive loss
of responsiveness to anti-Nogo-A antibodies with time after
the lesion was observed anatomically with regard to the re-
generation-enhancing effect of the antibody treatment. Acute
and 1-week-delayed treatment robustly increased regenera-
tion below the injury site; higher numbers of BDA-labeled
CST fibers with the irregular morphology typical of re-
generating fibers were found 0.5mm, 2.0mm, and 5.0mm
caudal to the lesion site in the anti-Nogo-A antibody-treated
groups. These regenerated fibers arborized extensively in the
grey matter and formed numerous varicosities, suggesting
that they formed synaptic connections and integrated into the
spinal circuitry. The 2-weeks-delayed treatment led to a
minimal increase in the number of labeled CST fibers in the
area immediately caudal to the injury site, and no increase
further below, indicating that the regeneration-enhancing ef-
fect on CST fibers was substantially decreased.
Several factors may explain why delayed treatment with
anti-Nogo-A antibodies is less effective. First, axotomized
CNS neurons show a transient lesion-induced growth re-
sponse after injury, which subsides after 1–2weeks and turns
into cellular atrophy (Plunet et al., 2002). Neutralizing Nogo-
A in the early post-injury phase may allow these sprouting
fibers to elongate and find targets that supply retrograde
trophic signals to the growing neurons, thus sustaining
growth and stabilizing the new connections. However, once
the lesion-induced intrinsic growth effort has stalled, de-
layed blockade of Nogo-A may be insufficient to promote
long-distance regeneration. Some types of CNS neurons,
such as rubrospinal neurons, can be stimulated to grow by
neurotrophins, even in an atrophic, shrunken state up to 1
year after axotomy, suggesting that combined neurotrophic
factors plus anti-Nogo-A antibody treatments may be one
way to extend the regeneration-permissive time window
(Kwon et al., 2002; Ylera et al., 2009). For example, the
combination of the neurotrophin NT3 and anti-Nogo-A an-
tibodies showed improved CST regeneration, even 2 months
after SCI (von Meyenburg et al., 1998). A second reason for
the lack of pronounced regeneration after 2-week-delayed
treatment may be the formation of scar tissue with its scar-
associated growth-inhibitory molecules. Different species of
CSPGs are secreted and accumulate within 1–4 weeks after
injury around CNS lesion sites ( Jones et al., 2002; Tang et al.,
2003). Some persist at the injury site for several months,
contributing to the barrier for regenerating axons ( Jones
et al., 2002; McKeon et al., 1999; Tang et al., 2003). Early
blockage of myelin inhibition, before scar-associated inhib-
itory proteins are deposited in large amounts, may therefore
be crucial.
The possible interference of scar tissue with anti-Nogo-A
antibody distribution by the CSF circulation could be ruled
out by measuring antibody concentrations in the CSF taken
from the cisterna magna, and by immunohistochemical
staining for mouse IgG in the spinal cord and brain tissue. The
high anti-Nogo-A and control antibody concentrations, be-
tween 20 and 30 lg/mL in the CSF in the 1-week-delayed
treatment animals, as well as the good antibody penetration
into the brain and spinal cord tissue in the 2-weeks-delayed
treatment groups, indicate that the antibodies were well dis-
tributed throughout the CNS.
Regenerating fibers of interrupted tracts and compensa-
tory growth of unlesioned axons have to form meaningful
connections with often distant target cells in the spinal cord.
During development, growing axons are guided by a com-
plex set of molecular cues that allow the correct formation
of neuronal circuits (Canty and Murphy, 2008). Subsequent
activity-dependent mechanisms then fine tune and stabi-
lize the circuitry in the late phases of development (Hua
and Smith, 2004; Martin, 2005). Little is known about the
mechanisms that guide regenerating axons to functionally
meaningful targets or stimulate intact neurons to form new
compensatory connections after an adult CNS injury. These
mechanismsmay be absent or failing in the denervated, non-
functional spinal cord with increasing time after injury. It is
noteworthy, however, that enhancement of compensatory
fiber growth with formation of functionally meaningful
connections by anti-Nogo-A antibodies can occur after
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stroke, even if the antibody application is delayed by 1 or 4
weeks (Markus et al., 2005; Seymour et al., 2005; Tsai et al.,
2007,2010). In contrast to the recovery from spinal cord le-
sions, stroke recovery may depend less on axon tract re-
generation and on fibers that regenerate through a CSPG-
rich lesion area.
Muscle spasms are a common consequence of spinal cord
injury. Their occurrence in a rat model for muscle spasms
was greatly reduced after anti-Nogo-A antibody treatment
(Gonzenbach et al., 2010). Importantly, 1- or 2-weeks-
delayed treatment with anti-Nogo-A antibodies was equally
effective as acute treatment. This anti-Nogo-A-antibody-
mediated reduction of muscle spasms with delayed treat-
ment might be due to increased plasticity of intraspinal
neuronal circuits, and not due to long-distance regeneration
of transected axons.
An increase of intraspinal plasticity (e.g., increased num-
bers of midline-crossing fibers after unilateral CST lesions)
has been observed as early as 1 week after SCI after anti-
Nogo-A antibody treatment (Bareyre et al., 2002). This
intraspinal plasticity could also contribute to the early
treatment response seen in the acutely treated group, per-
haps combined with early regenerating fibers (regeneration
velocity can be up to 1mm/day [Schnell and Schwab, 1990,
although the initial delay until fibers start to grow is un-
known).
In spite of standardized surgeries the variation of perfor-
mance level and lesion size is substantial in spinal cord lesion
experiments due to secondary injury effects like ischemic
necrosis and bleeding, which may limit the usefulness of the
conclusions of this study. However, all treatment groups had
similar lesion sizes, ranging around 50% injured tissue. In
addition, the random assignment to the delayed treatment
groups in pairs according to the initial motor function deficits
ensured valid control groups.
The present results show that the time frame for successful
treatment of spinal cord-injured adult rats with Nogo-A
blocking agents is restricted to less than 2 weeks after injury.
Our findings are of clinical importance, since a limited time
frame for successful Nogo-A blocking treatment is to be ex-
pected in human spinal cord-injured patients as well. The
duration of this time window may differ substantially be-
tween humans and rodents; the degenerative and regener-
ative changes after injury follow a markedly different time
course in the man and the rat. For example, the spinal shock
phase lasts for a few hours to about 2 days in rats, but from
days to 4 weeks in humans (Ditunno et al., 2004; Hierse-
menzel et al., 2000). The time course of motor function re-
covery after incomplete lesions is more protracted in
humans, who show motor improvements over several
months, whereas rats usually reach a plateau 4–6 weeks after
injury. Although the time frame for successful treatment
may thus be wider in humans than in rodents, our results
indicate that the treatment’s success is greater if it is started
early after injury. The present study also implies that anti-
Nogo-A antibodies alone may not be very effective in the
chronic stage of spinal cord injury. Strategies combining
different treatments that tackle the problem on different
levels (e.g., neuronal growth stimulation as well as scar
suppression) may provide the key to overcoming the
blockage of regeneration in chronic paraplegic and tetra-
plegic patients.
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